Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Bavarian Nordic A/S    BAVA   DK0015998017

BAVARIAN NORDIC A/S (BAVA)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
08/13/2018 08/14/2018 08/15/2018 08/16/2018 08/17/2018 Date
192.2(c) 189.25(c) 181.95(c) 177(c) 170.05(c) Last
137 959 95 822 198 312 325 295 884 636 Volume
+0.03% -1.53% -3.86% -2.72% -3.93% Change
More quotes
Financials (DKK)
Sales 2018 583 M
EBIT 2018 -306 M
Net income 2018 -297 M
Finance 2018 1 750 M
Yield 2018 -
Sales 2019 980 M
EBIT 2019 -1,93 M
Net income 2019 -28,8 M
Finance 2019 1 829 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019 118,75
EV / Sales2018 6,43x
EV / Sales2019 3,74x
Capitalization 5 494 M
More Financials
Company
Bavarian Nordic A/S focuses on the development, manufacturing and commercialization of cancer immunotherapies and vaccines for infectious diseases.It specializes in cancer immunotherapy which includes cancer pipeline, which focuses on therapeutic vaccines for breast, lung, ovarian and prostate... 
Sector
Pharmaceuticals
Calendar
09/07Presentation
More about the company
Surperformance© ratings of Bavarian Nordic A/S
Trading Rating : Investor Rating :
More Ratings
Latest news on BAVARIAN NORDIC A/S
08/16BAVARIAN NORDIC A/S : Announces First Half 2018 Results
GL
08/14BAVARIAN NORDIC A/S : New support for biotech company Bavarian Nordics vaccine p..
AQ
08/13BAVARIAN NORDIC A/S : half-yearly earnings release
08/13EUROPA-#INVESTEU : European support for Bavarian Nordic's vaccine production
AQ
08/11#INVESTEU : European Support for Bavarian Nordic's Vaccine Production
AQ
08/10BAVARIAN NORDIC A/S : Granted EUR 30 Million Loan from The European Investment B..
AQ
08/09BAVARIAN NORDIC A/S : Granted EUR 30 Million Loan from The European Investment B..
GL
08/09BAVARIAN NORDIC A/S : Announces Positive Data from Phase 2 Extension Study of it..
AQ
08/08BAVARIAN NORDIC A/S : to Host First Half 2018 Results Conference Call
GL
08/08BAVARIAN NORDIC A/S : Announces Positive Data from Phase 2 Extension Study of it..
GL
More news
Sector news : Pharmaceuticals - NEC
08/18ASTRAZENECA : Biopharma Spinout Entasis Files for IPO
DJ
08/17BAYER : Rejects Media Report of Fresh Dicamba Lawsuits
DJ
08/17Bayer says dicamba report not new
RE
08/17NOVO NORDISK A/S : Invests in Diabetes Treatment With Deal That Could Exceed $80..
DJ
08/17SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
More sector news : Pharmaceuticals - NEC
Latest Tweets
07/23? Nasdaq is proud to welcome to the Nasdaq International Designation Program..
3
07/15Head to Head Survey: BAVARIAN NORDIC/S $BVNRY & Fennec Pharmaceuticals $F.. 
07/14BAVARIAN NORDIC/S $BVNRY versus Genocea Biosciences $GNCA Head to Head Review.. 
07/11Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combinat.. 
06/30Head to Head Comparison: Solid Biosciences $SLDB versus BAVARIAN NORDIC/S $BV.. 
More tweets
Qtime:41
News from SeekingAlpha
08/16Bavarian Nordic A/S' (BVNKF) CEO Paul Chaplin on Q2 2018 Results - Earnings C.. 
08/16Bavarian Nordic A/S 2018 Q2 - Results - Earnings Call Slides 
08/16Bavarian Nordic A/S reports Q2 results 
06/19Bavarian Nordic (BVNRY) Presents At Citi 2018 European Healthcare Conference .. 
05/24Bavarian Nordic A/S (BVNKF) CEO Paul Chaplin on Q1 2018 Results - Earnings Ca.. 
Chart BAVARIAN NORDIC A/S
Duration : Period :
Bavarian Nordic A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BAVARIAN NORDIC A/S
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 294  DKK
Spread / Average Target 73%
EPS Revisions
Managers
NameTitle
Paul Chaplin President & Chief Executive Officer
Gerardus Wilhelmus van Odijk Chairman
Henrik Birk Chief Operating Officer & Executive Vice President
Ole Larsen Chief Financial Officer & Executive Vice President
Christopher R. Heery Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
BAVARIAN NORDIC A/S-24.19%843
JOHNSON & JOHNSON-5.18%360 750
PFIZER16.21%246 736
NOVARTIS0.10%211 093
ROCHE HOLDING LTD.-2.66%208 211
MERCK AND COMPANY22.73%183 667